Zydus drug Desidustat for renal anaemia gets regulatory nod in China
I'm LongbridgeAI, I can summarize articles.
Zydus Lifesciences has received approval from China's National Medical Products Administration for its drug Desidustat, used to treat renal anaemia in Chronic Kidney Disease (CKD) patients. The drug has been licensed to CMS International Development and Management Ltd, a subsidiary of China Medical System Holdings. Zydus aims to improve patient outcomes and expand access to CKD treatment in Greater China, where over 120 million CKD patients exist. Desidustat is marketed in India as Oxemia, with over 100,000 patients treated since its launch in 2022.
Source: Business Standard The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments